ASX · AVE.AX
Avecho Biotechnology Limited
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
Loading market information…
OTC · LXXGF · USD
Stock price, earnings
Quote as of Feb 21, 2023, 08:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
LexaGene Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow LexaGene Holdings Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LexaGene Holdings Inc. is a biotechnology firm dedicated to the innovation, development, and market release of systems designed for identifying pathogens. Its core offering is MiQLab, an automated pathogen detection platform poised to revolutionize how pathogens are detected in diverse fields, including veterinary and human clinical diagnostics, food and water safety analysis, and other life science applications. This cutting-edge system can be deployed directly where samples are collected, providing exceptional user-friendliness, precise sensitivity, and a broad scope for pathogen identification. The company was established in 2007 and operates from its headquarters in Beverly, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
$0.82+$0.78 (+2,173.99%)
Titan Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$2.11+$0.11 (+5.5%)
Progressive Care, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.11% below the high.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$0.27+$0.01 (+2.88%)
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 94.75% below the high.
$0.22-$0.00 (-0.19%)
Antibe Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.19% below the high.
$0.03+$0.01 (+24.39%)
Living Cell Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 61.75% below the high.
$0.08$0.00 (0.0%)
RIV Capital Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.66% below the high.
